Fidaxomicin Market Growth Analysis & Regional Outlook
Forecasts to 2025
Fidaxomicin is a macrolide antibacterial drug specified for the treatment of Clostridium
Difficile-Associated Diarrhea. The antibiotic Fidaxomicin drug kills bacteria in the
intestines. Fidaxomicin is the first in a new class of macrocyclic antibiotics and lately
been licensed by the European Medicines Agency (EMA).
Global Fidaxomicin Market is expected to grow at a significant CAGR in the upcoming years as the
scope and its applications are rising enormously across the globe. Fidaxomicin is also termed as
Difimicin, or Tiacumicin B, or Lipiarmicin, or Lipiarrmycin, or Lipiarmycin. It is a macrolide
antibacterial drug specified for the treatment of Clostridium Difficile-Associated Diarrhea. The
antibiotic Fidaxomicin drug kills bacteria in the intestines. Fidaxomicin is the first in a new class of
macrocyclic antibiotics and lately been licensed by the European Medicines Agency (EMA).
Fidaxomicin is a drug that is not used to treat infections that are not associated to Clostridium
difficile. The drug will not work for viral infections, colds, or flu.
Browse Full Research Report @
https://www.millioninsights.com/industry-reports/fidaxomicin-market